EU Shifts To Centralized OTC Process At Member States’ Expense – GSK Exec
This article was originally published in The Tan Sheet
Executive Summary
Europe's development of a centralized process for approving nonprescription pharmaceuticals is sapping the resources of the regulatory agencies of European Union member states, a GlaxoSmithKline regulatory executive says
You may also be interested in...
First EU Centralized Switch Goes To Alli, Could Spark More Applications
Central process will doubtless attract other switches, but countries will determine whether drug is still sold from pharmacies.
First EU Centralized Switch Goes To Alli, Could Spark More Applications
Central process will doubtless attract other switches, but countries will determine whether drug is still sold from pharmacies.
EU Needs OTC Regulatory Overhaul, Automatic Product Approval – AESGP
Europe's nonprescription drug industry wants to revamp European Union over-the-counter regulations and open market access by streamlining the product approval process, standardizing advertising rules and extending exclusivity protections